An Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of SAR245408 Administered Orally Daily in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2014
At a glance
- Drugs Pilaralisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 02 Dec 2014 Status changed from active, no longer recruiting to completed, according ClinicalTrials.gov record.
- 19 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 18 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.